AMGEN Inc

NASDAQ: AMGN
$337.38
+$1.43 (+0.4%)
Closing Price on September 20, 2024

AMGN Articles

The September 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data have been compared with the previous report, and short interest in...
The August 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors. Here we identify some of the top health care picks.
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The top analyst upgrades, downgrades and other research calls from Monday includes Ally Financial, Amgen, AT&T, BP, Chesapeake Energy, Expedia, National Oilwell Varco, Square, Synchrony and...
The July 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger health care companies that are about to report their quarterly results.
The June 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest moves...
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the top companies are starting to apply...
The May 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Amgen shares made a slight gain on Tuesday after it was announced that the FDA approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture.
Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.